PDG61 TYPES OF ENDPOINTS OF NEW MOLECULAR ENTITIES APPROVED BY THE FDA: THE INCREASING IMPORTANCE OF PATIENT-REPORTED OUTCOMES
May 1, 2020, 00:00
10.1016/j.jval.2020.04.347
https://www.valueinhealthjournal.com/article/S1098-3015(20)30535-0/fulltext
Title :
PDG61 TYPES OF ENDPOINTS OF NEW MOLECULAR ENTITIES APPROVED BY THE FDA: THE INCREASING IMPORTANCE OF PATIENT-REPORTED OUTCOMES
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30535-0&doi=10.1016/j.jval.2020.04.347
First page :
Section Title :
Open access? :
No
Section Order :
10217